Evicenter
Imbruvica (ibrutinib) in Chronic lymphocytic leukemia and small lymphocytic lymphoma
Manufacturer
Pharmacyclics LLC; Janssen Biotech, Inc.
Prescribing information
Imbruvica (opens in a new tab)
Questions
58
Last updated

All questions

Dosing and administration: Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma

7 questions · 4 sources

Dosing

What is the Imbruvica dose for CLL/SLL?

What is the maximum dose of Imbruvica?

Note: The Prescribing Information describes 840 mg as 2 times the maximum approved recommended dosage and 1680 mg as 4 times the maximum recommended dose; both correspond to the recommended dosage of 420 mg once daily.

How many mL of Imbruvica oral suspension is a 420 mg dose?

Note: The 6 mL volume is from the dose modifications table of the RESONATE-2 brochure that the dosing page links; the concentration is from the How Supplied section of the Prescribing Information.

How is the Imbruvica dose reduced for non-cardiac side effects?

Note: The spans are the rows of Table 2 for the starting dose of 420 mg, which applies to CLL/SLL.

How is Imbruvica adjusted for heart failure or arrhythmias?

Note: The label spans are the rows of Table 2 for the starting dose of 420 mg, which applies to CLL/SLL.

Treatment combinations

Should Imbruvica be taken before rituximab or obinutuzumab on infusion days?

Treatment duration

How long do patients stay on Imbruvica for CLL (RESONATE-2)?

Applies to Adults with previously untreated (first-line) CLL/SLL

Note: The 74-month median is from the up to 8-year follow-up of RESONATE-2, which the dose modifications page cites (Barr et al., Blood Adv 2022) and which is not included in the Prescribing Information.